Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | YAP1 | P46937 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23397828 | 1.00 | ACE (0.44) | ACECPB2CPB1KDM4EPOLB | |
| SCHEMBL31270648 | 0.90 | ACE (0.41) | ACECPB2CPB1ITGB3ITGA2B | |
| SCHEMBL18218810 | 0.88 | CPB2 (0.45) | ACECPB2CPB1ITGB3ITGA2B | |
| SCHEMBL13650201 | 0.87 | ITGB3 (0.45) | ACECPB2CPB1ITGB3ITGA2B | |
| SCHEMBL3008889 | 0.87 | ITGB3 (0.45) | ACECPB2CPB1ITGB3ITGA2B | |
| SCHEMBL3008885 | 0.87 | ITGB3 (0.45) | ACECPB2CPB1ITGB3ITGA2B | |
| Benzene SCHEMBL29402026 | 0.86 | ACE (0.47) | ACECPB2CPB1ITGB3ITGA2B | |
| SCHEMBL18207164 | 0.85 | KDM4E (0.35) | ACEKDM4EPOLBMEN1KMT2A | |
| SCHEMBL18207163 | 0.85 | KDM4E (0.35) | ACEKDM4EPOLBMEN1KMT2A | |
| SCHEMBL31270834 | 0.82 | MEN1 (0.40) | POLBMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020386-B2 | Methods and compositions for preventing opioid abuse | ALBANY MOLECULAR RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11020386-B2 | Methods and compositions for preventing opioid abuse | ALBANY MOLECULAR RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-10695342-B2 | Methods and compositions for preventing opioid abuse | ALBANY MOLECULAR RESEARCH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10695342-B2 | Methods and compositions for preventing opioid abuse | ALBANY MOLECULAR RESEARCH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10226456-B2 | Methods and compositions for preventing opioid abuse | 3ST RESEARCH LLC (US) | 2019-03-12 | — | — | US | disclosed |
| US-10226456-B2 | Methods and compositions for preventing opioid abuse | 3ST RESEARCH LLC (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-08 | — | — | US | disclosed |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-08 | — | — | US | disclosed |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-01 | — | — | US | disclosed |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-01 | — | — | US | disclosed |
| US-20160326182-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226456-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | ACE 822/4885CPB2 1461/4885CPB1 1533/4885 |
| US-10695342-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | ACE 822/4885CPB2 1461/4885CPB1 1533/4885 |
| US-11020386-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | ACE 822/4885CPB2 1461/4885CPB1 1533/4885 |
| US-20160326182-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | ACE 822/4885CPB2 1461/4885CPB1 1533/4885 |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | ACE 822/4885CPB2 1461/4885CPB1 1533/4885 |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | ACE 822/4885CPB2 1461/4885CPB1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.